Evidence map›Paper›PMID 31108832›Full record

ReviewInternational journal of molecular sciences2019

Epigenetic Control of Gene Expression in the Normal and Malignant Human Prostate: A Rapid Response Which Promotes Therapeutic Resistance.

Fiona M Frame, Norman J Maitland

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. International journal of molecular sciences · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Epigenetics of Urological Cancers.International journal of molecular sciences · 2019
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fiona M FrameThe Cancer Research Unit, Department of Biology, University of York, Heslington, York YO10 5DD, UK. fiona.frame@york.ac.uk.
Norman J MaitlandThe Cancer Research Unit, Department of Biology, University of York, Heslington, York YO10 5DD, UK. n.j.maitland@york.ac.uk.

Funding

European Community PITN-GA-2009-238278Prostate Cancer UK RIA15-ST2-022York Against Cancer N/AYorkshire Cancer Research Y257PA
6 · The paper itself

Abstract

A successful prostate cancer must be capable of changing its phenotype in response to a variety of microenvironmental influences, such as adaptation to treatment or successful proliferation at a particular metastatic site. New cell phenotypes emerge by selection from the large, genotypically heterogeneous pool of candidate cells present within any tumor mass, including a distinct stem cell-like population. In such a multicellular model of human prostate cancer, flexible responses are primarily governed not only by de novo mutations but appear to be dominated by a combination of epigenetic controls, whose application results in treatment resistance and tumor relapse. Detailed studies of these individual cell populations have resulted in an epigenetic model for epithelial cell differentiation, which is also instructive in explaining the reported high and inevitable relapse rates of human prostate cancers to a multitude of treatment types.

Indexed as

Epigenesis, GeneticGene Regulatory NetworksCell DifferentiationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMaleMutationNeoplastic Stem CellsProstateProstatic Neoplasmsdifferentiationepigeneticsheterogeneityprostate cancertumor-initiating cells

Identifiers

PMID31108832
PMCPMC6566891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.